ProKidney releases updated corporate presentation; no specific financial or clinical updates

PROKIDNEY CORP.

Company filed an updated investor presentation under Item 7.01 for January 2024.
Presentation highlights REACT renal autologous cell therapy for dialysis prevention.
No new financial data, clinical trial results, or guidance changes were disclosed.
Presentation is available on the company's investor relations website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.